Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog

• Published in: Cardiovascular research 1993-05, Vol.27 (5), p.832-838
• Main Authors: Yao, Zhenhai, Auchampach, John A, Pieper, Galen M, Gross, Garrett J
• Format: Article
• Language: English
• Subjects: Animals; Antianginal agents. Coronary vasodilator agents; Biological and medical sciences; Cardiovascular system; catalase; Catalase - metabolism; Disease Models, Animal; Dogs; endotoxin; Endotoxins - pharmacology; Female; Heart - drug effects; infarct size; Lipid A - analogs & derivatives; Lipid A - pharmacology; Male; Medical sciences; monophosphoryl lipid A; myeloperoxidase activity; Myocardial Infarction - enzymology; Myocardial Infarction - pathology; myocardial ischaemia; Myocardial Reperfusion Injury - enzymology; Myocardial Reperfusion Injury - pathology; Myocardium - enzymology; Myocardium - pathology; neutrophils; Peroxidase - metabolism; Pharmacology. Drug treatments
• ISSN: 0008-6363; 1755-3245
• DOI: 10.1093/cvr/27.5.832

Objective: The major objective of the present study was to determine the effects of a new endotoxin analogue, monophosphoryl lipid A (MLA), on myocardial infarct size in dogs. A second aim was to determine if potential cardioprotective effects of MLA might be mediated via an enhancement of antioxidant defence mechanisms. Methods: Barbiturate anaesthetised dogs were subjected to a 60 min left circumflex coronary artery occlusion followed by 5 h reperfusion. Either of two different doses of MLA (30 and 100 μg·kg−1) or an equivalent volume of vehicle were given intravenously 24 h prior to the infarct experiments. Transmural myocardial blood flow was measured at 30 min of occlusion by the radioactive microsphere technique and infarct size was determined at the end of 5 h of reperfusion by triphenyltetrazolium staining. Tissue catalase and myeloperoxidase activities were measured at 5 h of reperfusion as indices of antioxidant activity and neutrophil infiltration, respectively. Results: There were no significant differences between groups in systemic haemodynamic variables, myocardial oxygen demand, ischaemic bed size, or coronary and collateral blood flow to the ischaemic region. However, administration of MLA produced a marked dose dependent reduction in myocardial infarct size: 19.8(SEM 3.7)% and 14.1(2.5)%, respectively, v 32.7(2.9)% in the vehicle control group, p < 0.05. Pretreatment with either 30 or 100 μg·kg−1 of MLA resulted in small increases in tissue catalase activity in the non-ischaemic region of the heart: 0.169(0.033) and 0.197(0.013) K·g−1, respectively, v 0.136(0.013) K·g−1 tissue in the control; however, the increases were not statistically significant by ANOVA. Myeloperoxidase activity in the border zone immediately adjacent to the infarct was markedly decreased in both MLA treated groups: MLA 30 μg·kg−1, 2.69(0.82); MLA 100 μg·kg−l, 2.49(0.47), v control group, 5.81(1.20) units·g−1 tissue; p < 0.05. Conclusions: These data are the first to show a marked cardioprotective effect of a lipid A derivative of endotoxin in an in vivo model of myocardial infarction. Although the mechanism responsible for the reduction in infarct size by MLA is unknown, a reduction in neutrophil migration at the site of ongoing tissue injury, the border zone, may be partially responsible. Cardiovascular Research 1993;27:832-838